Table 3 Complication of malignancy
(A) | PM | DM | CADM | ||
|---|---|---|---|---|---|
ILD (N = 11) | No ILD (N = 12) | ILD (N = 11) | No ILD (N = 13) | ILD (N = 15) | |
Past history | Â | Â | Â | Â | Â |
  Number of patients | 1 | 1 | 0 | 0 | 1 |
  Primary site | gastric (ad) | lung (ad) |  |  | prostate (ad) |
Newly diagnosed | Â | Â | Â | Â | Â |
  Number of patients | 0 | 3 | 1 | 9 | 1 |
  Primary site (histology) |  | CML | breast (meta) | nasopharyngeal (sq) | ovarian (clear) |
| Â | Â | ML (MALT) | Â | lung (sq;1, ad;1) | Â |
| Â | Â | colorectal (ad) | Â | gastric (ad;3) | Â |
| Â | Â | Â | Â | oropharyngeal (sq) | Â |
| Â | Â | Â | Â | ML (DLBCL) | Â |
| Â | Â | Â | Â | Thymoma (typeB3) | Â |
(B) | Odds ratio (95 % CI) | Â | P value | Â | Â |
Univariate analysis | Â | Â | Â | Â | |
  PM | 0.387 (0.0615–1.73) | 0.218 |  |  | |
  DM | 5.87 (1.41–30.2) | 0.0106 |  |  | |
  CADM | 0.191 (0.00411–1.51) | 0.155 |  |  | |
  ILD | 0.0652 (0.00628–0.350) | 0.000126 |  |  | |
Multivariate analysis | Â | Â | Â | Â | |
  DM | 5.21 (1.17–23.1) | 0.0299 |  |  | |
  ILD | 0.0688 (0.0127–0.372) | 0.00190 |  |  | |